cy5 labeled notch1 antibody (Bioss)
Bioss is a verified supplier 
Bioss manufactures this product 
90
Structured Review
Bioss
cy5 labeled notch1 antibody
Cy5 Labeled Notch1 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cy5+labeled+notch1+antibody/Notch1+MOTC+Polyclonal+Antibody%2C+Cy5+Conjugated/pm34651637-215-46-50
Average 90 stars, based on 1 article reviews
Cy5 Labeled Notch1 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cy5+labeled+notch1+antibody/Notch1+MOTC+Polyclonal+Antibody%2C+Cy5+Conjugated/pm34651637-215-46-50
Average 90 stars, based on 1 article reviews
cy5 labeled notch1 antibody - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Incubation:Article Title: A microfluidic platform enables comprehensive gene expression profiling of mouse retinal stem cells. Article Snippet: Loss of photoreceptors due to retinal degeneration is a major cause of untreatable visual impairment and blindness.. Cell replacement therapy, using retinal stem cell (RSC)-derived photoreceptors, holds promise for reconstituting damaged cell populations in the retina.. One major obstacle preventing translation to the clinic is the lack of validated markers or strategies to prospectively identify these rare cells in the retina and subsequently enrich them. Blocking Assay:Article Title: A microfluidic platform enables comprehensive gene expression profiling of mouse retinal stem cells. Article Snippet: Loss of photoreceptors due to retinal degeneration is a major cause of untreatable visual impairment and blindness.. Cell replacement therapy, using retinal stem cell (RSC)-derived photoreceptors, holds promise for reconstituting damaged cell populations in the retina.. One major obstacle preventing translation to the clinic is the lack of validated markers or strategies to prospectively identify these rare cells in the retina and subsequently enrich them. |